FOR IMMEDIATE RELEASE [Covington, KY ~ June 25, 2020] CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization (CRO) was named Champion in multiple categories of the 2020 CRO Leadership Awards, and was the only CRO named as Champion in the Quality category.
In its 8th year, Life Science Leader magazine partnered again with Industry Standard Research (ISR) to determine the recipients of the 2020 CRO Leadership Awards. CTI won an award in 5 of the 6 categories, including Capabilities, Compatibility, Expertise, Quality, and Reliability. CTI was also the only CRO to be recognized as "Champion" in all 5 of those categories as well, which means the company scored 1½ standard deviation or more above the weighted average in each of the core categories. CTI was the only Champion in the Quality category, outperforming nearly 30 other recognized CROs from around the world.
Winners of the awards are determined using primary market research conducted by ISR. Sponsors provide ratings of CROs based on recent outsourced projects, and this experiential feedback is analyzed by sponsor company size to reveal leading CROs in different performance categories. This is the third year in a row that the CTI team has been recognized at the CRO Leadership Awards.
"The CTI team has always been dedicated to providing the highest quality service to our sponsors," remarks Timothy Schroeder, Founder and CEO of CTI. "Congratulations to the other 30 or so CROs, who were chosen out of thousands for their high standards. We are extremely proud to be recognized as the CRO with the highest quality in the world. We pride ourselves on all of these award qualities - being reliable, providing expertise, being easy to work with, etc., and it is an honor to consistently hear from an external, unbiased source that we are successful in demonstrating those characteristics to our partners."
The company, with an annual average staff retention rate of 95%, has been working for three decades in the drug development industry across North America, Europe, Latin America, Asia-Pac, and Middle East, specializing in clinical research programs involving critically ill patient populations, and has more than 30 offices worldwide to serve more than 200 pharmaceutical, biotechnology, and medical device clients. The company is currently managing more than a fifteen active COVID-19 trials for treatment and prevention.